Myomo

Scores by criterion

Each criterion is defined on our methodology page.

Who uses Myomo and what it's for

MyoPro is prescribed for people with weakness or partial paralysis in the arm and hand after a stroke, brachial plexus injury, or other neuromuscular condition.^1,6 It is referred at rehabilitation centers including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute, and twenty Veterans Affairs hospitals.²

The buyer is usually an insurer. Myomo says it has in-network access to more than 100 million covered lives, including Medicare and VA patients, and in 2026 added state contracts with Anthem Blue Cross Blue Shield plans.³

A brace driven by the wearer’s own muscle signals

When the wearer tries to move, sensors in the brace detect the weak muscle signal and a motor moves the arm in that direction, so the person controls the motion. Myomo says this lets users feed themselves, carry objects, and do household tasks.⁶

The technology came from MIT and Harvard Medical School research. Myomo licensed MIT's patents in 2006, and its first robotic elbow brace received FDA approval in 2007.^6,7

Orders and referrals reported each quarter

In the second quarter of 2026 Myomo booked a record 255 orders, added 739 patients to its pipeline, and reported an average selling price of about $55,500. Revenue rose 21% to $11.7 million while operating expenses grew less than 1%.³

More than half of that quarter's revenue came from recurring sources such as clinician referrals, orthotic and prosthetic partners, and the VA. A randomized controlled trial at the University of Utah had enrolled 25 of a planned 50 subjects.³

Prices set by Medicare

The Centers for Medicare and Medicaid Services set fee schedule rates of $33,480.90 for the MyoPro Motion W and $65,871.74 for the Motion G, effective April 1, 2024.⁵ Because private insurers and the VA negotiate their own rates, the average selling price Myomo reports is the best guide to what the device brings in.³

Competition

Myomo's annual report says powered arm braces face only a few direct rivals, naming Neurolutions in the US and Vincent Systems and HKK Bionics in Germany. It also lists implants that stimulate the vagus nerve, such as MicroTransponder's, and non-powered braces. We compare the MyoPro with one product from each group.¹¹

Source: Robotics Reviewed analysis of company product pages, filings, and announcements, October 2026.

Limits

Every unit has to be prescribed, custom fitted by a trained clinician, and approved by an insurer, which slows adoption and makes the path to a device longer than a typical purchase.^2,3

Losses continue. Myomo reported a net loss of $4.0 million in the second quarter of 2026, including a $1.2 million non-cash charge.³

Guidance has moved around. In 2025 Myomo lowered its full-year revenue guidance to $40 million to $42 million and reported a wider second-quarter loss, and AInvest reported that its shares fell about 9% in a September 17, 2025, session after those results. In 2026 it raised guidance.^10,3

What customers say

Where it helps

Myomo also points to published clinical research showing an immediate, clinically significant reduction in upper extremity impairment with MyoPro.²

Where it falls short

We found no independent patient reviews to quote. The drawbacks in public material are insurance approval, the fitting process, and the company's continued losses.³

Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Myomo financial results, Medicare fee schedule announcement, and patient stories.

Leadership

• 

  Paul R. Gudonis

  Chairman and chief executive officer

  Gudonis has led Myomo since 2011. He previously ran Genuity and Centra Software and helped introduce AT&T's first cellular service.¹⁵

  Read full profile

• Katie McClure

  Chief commercial officer

  McClure leads Myomo's commercial organization.⁹

• David Henry

  Chief financial officer

  Henry is Myomo's chief financial officer.⁹

• Dr. Harry Kovelman

  Chief medical officer

  Dr. Kovelman is Myomo's chief medical officer.⁹

Sources